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Abstract
Background: Elevated levels of serum indoxyl sulfate (IS) have been linked to cardiovascular complications in
patients with chronic kidney disease (CKD). Oral sorbent therapy using spherical carbons selectively attenuates IS
accumulation in CKD patients. This study aimed to investigate whether oral administration of a new oral spherical
carbon adsorbent (OSCA), reduces serum IS levels in moderate to severe CKD patients.
Methods: This prospective, multicenter, open-label study enrolled patients with CKD stages 3–5. Patients were
prescribed OSCA for 8 weeks (6 g daily in 3 doses) in addition to standard management. Serum IS levels were
measured at baseline and 4 and 8 weeks of treatment with OSCA.
Results: A total of 118 patients were enrolled and 87 eligible patients completed 8 weeks of study. The mean age
of the study subjects was 62.8 ± 13.7 years, and 80.5% were male. Baseline levels of serum IS were negatively
correlated with estimated glomerular filtration rate (eGFR) (r = − 0.406, P < 0.001) and increased with increasing CKD
stages (stage 3, 0.21 ± 0.21 mg/dL; stage 4, 0.54 ± 0.52 mg/dL; stage 5, 1.15 ± 054 mg/dL; P for trend = 0.001). The
patients showed significant reduction in serum total IS levels as early as 4 weeks after OSCA treatment (22.5 ± 13.9%
reduction from baseline, P < 0.001) and up to 8 weeks (31.9 ± 33.7% reduction from baseline, P < 0.001). This
reduction effect was noted regardless of age, kidney function, or diabetes. No severe adverse effects were reported.
Gastrointestinal symptoms were the most commonly reported adverse effects. In total, 21 patients withdrew from
the study, with dyspepsia due to heavy pill burden as the most common reason. The medication compliance rate
was 84.7 ± 21.2% (min 9%, max 101%) for 8 weeks among those who completed the study.
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Conclusions: OSCA effectively reduced serum IS levels in moderate to severe CKD patients. Gastrointestinal
symptoms were the most commonly reported complications, but no treatment-related severe adverse effects were
reported.
Trial registration: Clinical Research Information Service (KCT0001875. 14 December 2015.)
Keywords: Chronic kidney disease, Indoxyl sulfate, Carbon adsorbent, Oral spherical carbon adsorbent, Uremic toxin
Background
Patients with chronic kidney disease (CKD) have higher
rates of cardiovascular (CV) morbidity and mortality
than the general population [1–3]. Non-traditional risk
factors, including increased inflammation, endothelial
dysfunction, vascular calcification, and uremic toxins,
that are relevant to patients with CKD may result in in-
creased CV events [4–8]. Indoxyl sulfate (IS), a protein-
bound uremic toxin, is a dietary tryptophan metabolite
[9, 10]. Ingested tryptophan is converted to indole by in-
testinal microbiota, absorbed into the intestine, and con-
verted into IS by the liver [11]. IS is eventually excreted
into the urine via proximal tubular secretion. However,
in patients with CKD, decreased renal clearance leads to
an increase in blood and tissue levels of IS [12]. In-
creased IS levels are associated with renal inflammatory
gene activation and increased expression of profibrotic
genes and proteins leading to renal tubulointerstitial fi-
brosis [13–17]. These findings suggest that high levels of
IS act as nephrotoxins and are responsible for the pro-
gression of CKD.
Such toxicity to the kidney has prompted the develop-
ment of therapeutic strategies to reduce the levels of IS in
circulation through dialytic and non-dialytic treatments
[18]. As IS is derived from colonic microbiota metabolism,
there have been efforts to target the intestine to reduce its
production [11]. This has been done particularly through
maintaining normal gut homeostasis by modulating bacter-
ial growth in the colon, thus reducing bacterial toxin pro-
duction, or inhibiting gastrointestinal absorption of protein-
bound uremic toxin precursors by adsorbing and enhancing
their excretion into the feces [19]. Compared to conven-
tional renal replacement therapy, both treatment strategies
offer benefits in terms of lower costs, fewer complications,
and merits of application in non-dialysis CKD patients.
AST-120, a synthesized carbon adsorbent, has been used
in Asian countries to treat progressive CKD patients for
the last 10–20 years. This oral sorbent selectively adsorbs
indole in the lower intestinal tract and thereby attenuates
the systemic accumulation of IS in CKD patients. Benefits
of oral absorbents have been demonstrated in preclinical
and non-randomized clinical studies to reduce serum
levels of IS by 11.3 to 39% and improve clinical outcomes
[14, 20–25]. However, many patients report gastrointes-
tinal complications and difficulties in ingesting AST-120
in practice. Of note, the difficulties in ingesting a large
amount of medications and their adverse effect on medi-
cation compliance have been highlighted. Recently, a new
orally administered carbon adsorbent capsule was devel-
oped in Korea (Renamezin®, Daewon Pharm; Seoul, Korea)
(Additional file 1, Fig. S1A and 1B). In contrast to other
oral absorbents, this new oral spherical carbon adsorbent
(OSCA) uses furan resin as the raw material and is re-
ported to have 2 to 10 times greater compression strength
when compared with spherical carbonaceous adsorbents
made from petroleum pitch. However, there are no clinical
data regarding the efficacy of OSCA in reducing IS levels
in moderate to severe CKD patients.
The aim of this study was to investigate whether a
newly developed oral adsorbent, OSCA, effectively re-
duces serum levels of IS in moderate to severe CKD pa-
tients. In particular, the ability of OSCA to show
comparable benefits in CKD patients with diabetes as
well as in those without was evaluated. Furthermore, we
aimed to investigate the adverse effects and medication
compliance associated with OSCA.
Methods
Patient selection and study design
Moderate to severe CKD patients not on dialysis treat-
ment from six outpatient nephrology clinics in Korea
were enrolled for this prospective, open-label, observa-
tion study. Eligible patients were those 1) who provided
informed consent, 2) over 19 years of age, 3) with serum
creatinine levels of 1.5–5.0 mg/dL, and 4) who showed
no spontaneous improvement in or progression of renal
disease or any changes in their conventional treatments
for at least 3 months prior to the study. This study ex-
cluded patients with 1) a colonic transit disorder; 2) re-
current constipation; 3) peptic ulcer or gastroesophageal
varices; 4) uncontrolled hypertension; 5) cardiovascular
disease (coronary artery disease, myocardial ischemia,
cerebrovascular disease, or peripheral artery disease) in
the 6 months prior to enrollment; 6) uncontrolled
arrhythmia; 7) liver disease with serum aminotransferase
levels greater than 2 times the upper normal limit; 8)
history of alcohol abuse; and 9) active infection or in-
flammation, and patients who were 10) pregnant, lactat-
ing, or in the reproductive age desiring pregnancy or 11)
Kim et al. BMC Nephrology          (2020) 21:317 Page 2 of 10
those determined to be inappropriate for clinical study
by the investigators.
The study protocol was approved by each site’s institu-
tional review board (3–2015-0271, ClinicalTrials.gov
Identifier: NCT02681991) and performed in accordance
with the ethical principles of the Declaration of Helsinki.
All patients provided written informed consent before
participation in the study.
Data collection
All eligible patients’ medical charts were carefully
reviewed to identify any concomitant mediations and co-
morbidities. Standard management for CKD was pro-
vided to all study participants as follows: dietary
education on low-salt and low-protein diets (daily so-
dium less than 2.3 g and dietary protein of 0.6–0.8 g, re-
spectively) was provided to all participants at outpatient
clinic visits [26]. Hypertension was controlled with anti-
hypertensive medications, including angiotensin-
converting enzyme inhibitors (ACEIs) and/or angioten-
sin II receptor blockers (ARBs), calcium channel
blockers, and diuretics as needed. The new carbon ad-
sorbent medication, OSCA, was kindly provided by Dae-
won Pharmaceutical. The dose of OSCA used in this
study was the dose recommended to obtain renoprotec-
tive effects in progressive CKD patients, whose serum
creatinine concentrations were between 2.0 and 5.0 mg/
dL, by the Korean Ministry of Food and Drug Safety. Pa-
tients were instructed to take 6.0 g/day of OSCA (Rena-
mezin®, a total of 21 capsules daily) in 3 divided doses
for 8 weeks in addition to their standard management.
In order to investigate medication compliance rates to
mimic the outpatient clinic environment, patients were
encouraged to report any adverse events experienced
during the study period. Furthermore, the primary inves-
tigators of each institute were advised to discontinue this
regime for any individuals experiencing adverse events
with more than mild severity. The medication compli-
ance was assessed based on meticulous record-keeping
of the number of pills in the medication bottles returned
by each individual patient.
Patients were followed up prospectively at baseline
and at 4 and 8 weeks of treatment. At each visit, clinical
parameters, such as blood pressure, pulse rates, and
body weight, and laboratory parameters, including
complete blood cell count and serum phosphorus, serum
uric acid, blood urea nitrogen (BUN), serum creatinine,
serum albumin, serum electrolyte, and serum IS levels,
were measured. The estimated glomerular filtration rate
(eGFR) was calculated using the Modification of Diet in
Renal Disease Study (MDRD) equation [27]. Urine sam-
ples were collected in the morning after the first voiding,
and the urine protein to creatinine ratio (UPCR) were
calculated to assess proteinuria.
Measurement of serum indoxyl sulfate levels
Serum total IS levels were measured using a high-
performance liquid chromatography-fluorescence de-
tector (HPLC-FLD, Agilent 1100 series; Agilent Tech-
nologies, Santa Clara, CA) at an independent central lab
(Seoul Clinical Laboratories, Seoul, Korea). Participants’
serum samples (300 μL) were dispensed into 0.22-μm
nylon centrifugal filter tubes (F2517–1, National Scien-
tific; Claremont, CA) and centrifuged at 13,000 rpm for
5 min. The upper layers (200 μL) were collected into
HPLC vials, and 10 μl was injected into the HPLC-FLD
using an HPLC auto-sampler. A guard column (CAPC
ELLPAK MF, SG80 5m, 4.6 mm ID X 150mm, 40.0 °C;
Shiseido, Tokyo, Japan) was used. Eight standard sam-
ples of IS at concentrations from 0 to 10.0 mg/dL were
prepared for calibration. The flow rate was 1.0 mL/min,
and the total run time was 11 min. Fluorescence inten-
sities between 295 nm in excitation and 390 nm in emis-
sion were measured. The reference normal range of
serum IS derived from 150 healthy controls without any
underlying disease was 0.07 ± 0.04 mg/dL [28].
Sample size and statistical analysis
To estimate sample size, we used results from previous
clinical trials on oral adsorbents in CKD and dialysis pa-
tients [20–25]. Assuming a 25 to 30% reduction effect of
previous oral adsorbents on serum levels of IS, at least 50
patients were needed (α < 0.05 and power of 80%). Sample
size calculations were performed using the general power
analysis program (G*Power, http:// gpower.hhu.de/) [29].
Post-marketing data on oral adsorbents showed an up to
50% dropout rate. Therefore, a sample size of 120 patients
was initially needed for the study. Statistical differences in
the clinical characteristics before and after treatment with
OSCA were determined using Student’s t-test for continu-
ous variables. A repeated measures analysis of variance test
was used to determine the reduction of serum IS levels at 4
and 8weeks of treatment. The chi-squared test was used to
assess the degree of medication compliance and reduction
of serum sulfate levels. Pearson’s correlation coefficients
were used to assess the relationships between serum IS
levels and selected clinical or biochemical variables. Mul-
tiple linear regression analysis was performed to identify
factors independently associated with serum IS. All analyses
were performed using SPSS 23 software for Windows
(IBM; Armonk, NY), and data are presented as mean ±
standard deviation (SD) for continuous variables or fre-
quency (percentage) for categorical variables. P-values less
than 0.05 were considered to be statistically significant.
Results
Baseline characteristics
Table 1 shows the baseline demographic, clinical, and
biochemical characteristics of the 87 analyzed patients.
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The mean age of the study participants was 62.8 ± 13.7 years,
and 70 (80.5%) were male. The mean systolic and diastolic
blood pressure were 131.2 ± 11.7 and 79.0 ± 11.2mmHg. The
mean duration of CKD among total study subjects were
70.0 ± 47.2months and 95.4% of subjects were in CKD stage
3 or 4. The prevalence of hypertension was 77.0% and that of
diabetes were 48.3%. In the laboratory tests at baseline, mean
levels of IS were 0.46 ± 0.41mg/dL and mean eGFR levels
were 31.6 ± 11.3mL/min/1.73m2 among study subjects.
Association between serum indoxyl sulfate levels and
clinical parameters
Study participants showed serum IS levels greater by al-
most ten times when compared to the reference range at
baseline. Moreover, serum IS levels increased signifi-
cantly and progressively with increasing CKD stages
[stage 3, 0.21 ± 0.21 (reference); stage 4, 0.54 ± 0.52; stage
5, 1.15 ± 054 mg/dL; P for trend = 0.001, Fig. 1]. In line
with other previous studies, there was a significant nega-
tive correlation between serum IS levels and baseline
eGFR (r = − 0.406, P < 0.001, Fig. 2). Next, we performed
linear regression analysis to evaluate the correlation be-
tween serum IS levels and clinical parameters (Table 2).
In the univariable analysis, serum phosphorus and intact
parathyroid hormone (PTH) levels showed positive cor-
relation with serum IS levels. However, baseline eGFR
and hemoglobin (Hb) levels were negatively correlated
with serum IS levels. In multivariable analysis, only
eGFR was independently associated with serum IS levels
(coefficient β = − 0.013, P = 0.02).
Clinical parameters before and after treatment with OSCA
We compared various clinical parameters before and
after treatment with OSCA (Table 3). The body weight,
diastolic blood pressure, and hemoglobin level were sig-
nificantly reduced after OSCA treatment. However,
there were no significant differences in the levels of
BUN, serum creatinine, and eGFR.
OSCA treatment effectively reduces serum indoxyl sulfate
levels
Next, the efficacy of OSCA in reducing serum IS levels
was evaluated. Figure 3 shows the mean changes in
serum IS level from baseline at 4 and 8 weeks of OSCA
treatment for all subjects. OSCA administration signifi-
cantly reduced serum IS levels at 4 weeks (0.46 ± 0.42 vs.
0.36 ± 0.36 mg/dL, P < 0.001) and 8 weeks (0.31 ± 0.28
mg/dL, P < 0.001). The degree of reduction in serum IS
levels after 4 and 8 weeks of OSCA administration was
22.5 ± 13.9% and 31.9 ± 33.7%, respectively. However,
among subjects who were excluded due to failure to take
OSCA (n = 21), there were no decrease in serum IS
levels between baseline and 4 weeks after study enroll-
ment (Additional file 2, Fig. S2). We further performed
subgroup analysis, and serum IS levels significantly de-
creased regardless of age (< 60 vs. ≥60 years), eGFR cat-
egories (< 30 vs. ≥30mL/min/1.73 m2), and diabetes
(absent vs. present) (Fig. 4). In particular, patients with
diabetes showed a significant decrease in serum IS levels
at 8 weeks after OSCA treatment (0.49 ± 0.41 vs. 0.33 ±
0.27 mg/dL, P < 0.001). Patients without diabetes also
showed a significant decrease in serum IS levels at 8
weeks (0.43 ± 0.43 vs. 0.29 ± 0.28, P < 0.001).
Safety and drug compliance
The safety of OSCA was assessed in all enrolled patients
who received more than one dose of study medication
(n = 109) (Table 4). No severe adverse effects requiring
Table 1 Baseline characteristics of study participants
(n = 87)
Age (years) 62.8 ± 13.7
Sex, male (%) 70 (80.5)
BMI (kg/m2) 25.9 ± 4.1
Systolic BP (mmHg) 131.2 ± 11.7
Diastolic BP (mmHg) 79.0 ± 11.2
CKD duration (months) 70.0 ± 47.2
CKD stage
Stage 3 (%) 45 (51.7)
Stage 4 (%) 38 (43.7)




Cardiovascular disease 13 (14.9)
Cerebrovascular disease 10 (11.5)
Laboratory data
Indoxyl sulfate (mg/dL) 0.46 ± 0.41
BUN (mg/dL) 35.1 ± 12.7
Serum creatinine (mg/dL) 2.5 ± 0.8
eGFR (mL/min/1.73m2) 31.6 ± 11.3
Urine PCR (mg/g) 3613.4 ± 4203.2
Hemoglobin (g/dL) 12.1 ± 2.0
Phosphorus (mg/dL) 3.6 ± 0.6
Intact PTH (mg/dL) 104.0 ± 101.3
Uric acid (mg/dL) 7.1 ± 1.8
Albumin (g/dL) 3.9 ± 0.6
Serum Na (mmol/L) 139.5 ± 2.5
Serum K (mmol/L) 4.8 ± 0.6
Total CO2 (mmol/L) 23.8 ± 3.3
Data are presented as mean± standard deviation or number (percentage) of subjects
Abbreviation: BMI body mass index, BP blood pressure, CKD chronic kidney
disease, eGFR estimated glomerular filtration rate, PCR protein to creatinine
ratio, PTH parathyroid hormone
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admission were reported during the study. The most
commonly reported adverse effects were gastrointestinal
symptoms (dyspepsia, n = 10; constipation, n = 3; diar-
rhea, n = 3; vomiting, n = 2) followed by leg cramp (n =
1), generalized weakness (n = 1), and skin rash (n = 1). A
total of 22 patients were withdrawn from the study and
dyspepsia due to heavy pill burden owing to ingestion of
21 pills per day was the most common reason. The
intention-to-treat (ITT) population, including all pa-
tients who received at least one dose of the study
Fig. 1 Serum levels of indoxyl sulfate presented as a function of CKD stages. Abbreviation: CKD, chronic kidney disease
Fig. 2 Correlation between indoxyl sulfate and renal function (r = coefficient of linear regression). Abbreviation: eGFR, estimated glomerular
filtration rate
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medication and had at least one post-baseline renal
function measurement, was assessed for medication
compliance. In the ITT population, the medication com-
pliance rate was 84.7 ± 21.2% for the entire 8 weeks.
Discussion
This study demonstrated that the newly developed car-
bon adsorbent, OSCA, effectively reduces serum IS
levels in moderate to severe CKD patients. The baseline
serum IS levels were higher in patients with more ad-
vanced stages of CKD. However, at 4 and 8 weeks of
OSCA treatment, a significant reduction of serum IS
levels from baseline was observed. Furthermore, this re-
duction effect was independent of age, kidney function,
or diabetes. There were no serious side effects of the
study medication. The medication compliance rate was
84.7%, and the most common reason for withdrawal was
gastrointestinal side effects due to heavy pill burden.
A recent post-hoc subgroup analysis of the EPPIC-
USA study per protocol population data suggested that
oral absorbent administration might delay the time to
primary end point in CKD patients in the USA. A trend of
beneficial effects of oral absorbent administration was ob-
served in patients who had study drug compliance rates
greater than 67% and were treated for at least 8 weeks
[30]. These findings underscore the importance of good
patient compliance in achieving benefits of oral adsorbents
for preventing the systemic accumulation of uremic
toxins. However, in contrast to well-organized clinical
studies, many patients report gastrointestinal complica-
tions and difficulties in ingesting AST-120 in practice [31].
OSCA is a newly developed oral adsorbent consisting of
spherical carbon particles packed in capsules for conveni-
ence. An in vitro equilibrium study demonstrated a com-
parable affinity and capacity constant for indole between
OSCA and AST-120. Meanwhile, OSCA demonstrated
greater adsorption capacity for β-isobutyric acid and less
adsorption capacity for α-amylase. These in vitro results
suggest an improved selective adsorption capacity of
OSCA for indole, which is the main precursor of IS. Such
selective adsorption capacity may be due to the improved
preservation of the micropore structure by enhanced
Table 2 Association between baseline serum indoxyl sulfate levels and clinical parameters
Univariate Multivariable
B (95% CI) P B (95% CI) P
Age (per 1 year increase) 0.003 (−0.004 to 0.01) 0.36 –
BMI (per 1 kg/m2 increase) − 0.014 (− 0.035 to 0.008) 0.22 –
SBP (per 1 mmHg increase) 0.004 (− 0.004 to 0.012) 0.31 –
eGFR (per 1 mL/min/1.73m2 increase) −0.015 (− 0.022 to − 0.008) < 0.001 −0.013 (− 0.018 to0.001) 0.02
Log-transformed UPCR (per 1 increase) 0.028 (−0.050 to 0.107) 0.46 –
Hemoglobin (per 1 mg/dL increase) −0.074 (− 0.123 to − 0.031) 0.001 −0.012 (− 0.059 to 0.034) 0.60
Phosphorus (per 1 mg/dL increase) 0.263 (0.130 to 0.391) < 0.001 0.085 (−0.053 to 0.224) 0.22
Intact PTH (per 1 mg/dL increase) 0.002 (0.001 to 0.003) < 0.001 0.001 (0.000 to 0.002) 0.05
serum albumin (per 1 g/dL increase) −0.024 (− 0.183 to 0.135) 0.77 –
Abbreviation: BMI body mass index, SBP systolic blood pressure, eGFR estimated glomerular filtration rate, UPCR urine protein to creatinine ratio, PTH
parathyroid hormone
Table 3 Clinical parameters before and after treatment with OSCA
Before treatment (n = 87) After treatment (n = 87) P
Body weight (kg) 71.2 ± 13.9 70.6 ± 13.8 0.03
Systolic BP (mmHg) 131.2 ± 11.7 128.3 ± 16.1 0.06
Diastolic BP (mmHg) 79.0 ± 11.2 75.1 ± 11.2 0.01
Hemoglobin (g/dL) 12.1 ± 2.0 11.9 ± 1.9 0.04
Phosphorus (mg/dL) 3.6 ± 0.6 3.7 ± 0.7 0.07
Uric acid (mg/dL) 7.1 ± 1.8 7.3 ± 1.8 0.05
BUN (mg/dL) 35.2 ± 12.7 36.1 ± 12.7 0.37
Serum creatinine (mg/dL) 2.5 ± 0.8 2.6 ± 0.9 0.06
eGFR by Creatinine (mL/min/1.73m2) 31.7 ± 11.3 32.0 ± 13.1 0.57
Serum albumin (g/dL) 3.9 ± 0.6 3.9 ± 0.5 0.43
The paired t-tests were performed to compare the two groups
Abbreviation: OSCA oral spherical carbon adsorbent, BMI body mass index, BP blood pressure, CKD chronic kidney disease, eGFR estimated glomerular
filtration rate
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compression strength. This study is the first clinical study
to confirm that OSCA effectively reduces serum levels of
IS in moderate to severe CKD patients. OSCA demon-
strated up to 31.9% reduction of serum IS levels from
baseline, which is comparable to the results of previous
clinical studies on AST-120. Such reduction in serum
levels of IS was evident at 4 weeks of drug administration.
During the course of the present study, there were no sig-
nificant changes in renal function or blood pressure.
Moreover, nutritional parameters, such as serum albumin,
also did not show any significant changes during the study
period. Thus, it can be speculated that the reduction of
serum levels of IS observed in this study is mostly due to
OSCA administration.
Another aim of the study was to investigate the ad-
verse effects and medication compliance associated with
the study drug in a real clinical setting. The patients
were asked to report even the slightest discomfort, and
investigators of participating centers were advised to me-
ticulously interview patients to detect adverse effects re-
lated to the study drug. No severe treatment-related
adverse event was reported. This may have been due to
the short duration of the study in contrast to previous
EPPIC trials, wherein the median duration of treatment
was over 90 weeks. Conversely, OSCA binds to indole in
the intestine and is excreted with feces. Thus, it does
not accumulate in the body and has less chance to in-
duce toxic effects. Safety results show that the most fre-
quently occurring treatment-emergent and treatment-
related adverse events were mainly gastrointestinal dis-
orders. Overall, gastrointestinal symptoms were the most
commonly reported treatment-related adverse effect as
also seen in Japan and pooled analysis of EPPIC trials
[20, 32]. Symptoms, such as dyspepsia, constipation, and
diarrhea, accounted for the most reported gastrointes-
tinal symptoms. Most of the symptoms were mild to
moderate and none of them required hospitalization.
CKD patients belong to the group of patients with
chronic disease with the highest daily pill burden [33].
Patients in earlier stages of CKD are reported to take a
mean of 6–12 medications that increases depending on
the severity of their disease [34]. A high pill burden was
also prevalent in CKD patients in the present study with
more than 4.9 ± 3.6 medications daily. The addition of
study medications (21 pills/day) to patients’ daily medi-
cations may have contributed to the aggravation of
gastrointestinal symptoms and drop-out. Such a high pill
burden is usually associated with poor drug compliance.
The medication compliance rate was 84.0 ± 23.4% (min
9%, max 101%) in this study over 8 weeks of treatment.
Fig. 3 Changes in mean levels of serum indoxyl sulfate from baseline to 8 weeks after OSCA treatment. Abbreviation: OSCA, oral spherical
carbon adsorbent
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This percentage is rather low compared to that in previ-
ous clinical trials, which report a compliance rate of over
90%. The EPPIC trials showed high compliance rates
and supported the tolerability of oral adsorbent therapy
for long-term use. However, whether patients actually
took all 30 pills daily cannot be confirmed. Interestingly,
our patients showed improved compliance in the second
4 weeks of the study period, which may be attributable
to adjustment to the new medication.
The major limitation of this pilot study was that out-
comes in the intervention group were not compared
with those in a control group. It would have been better
to evaluate the efficacy of the study drug in comparison
to a placebo. However, at the time of study initiation,
OSCA had already been approved for the treatment of
progressive CKD in Korea. Therefore, it might not be
ethical or safe for patients allocated to the placebo group
to ingest so many placebo pills while already having a
high pill burden. Moreover, we additionally compared
serum IS levels among subjects who were excluded due
Fig. 4 Comparison of reduction in serum indoxyl sulfate by diabetes, age, and baseline renal function. Abbreviation: eGFR, estimated glomerular
filtration rate
Table 4 Drug compliance and adverse events
Total (n = 109)
Drug compliance
First 4 weeks compliance (%) 84.4 ± 21.2
Second 4 weeks compliance (%) 91.6 ± 14.9
Whole period compliance (%) 84.7 ± 21.2
Adverse events
Dyspepsia (%) 10 (47.6)
Diarrhea (%) 3 (14.3)
Constipation (%) 3 (14.3)
Vomiting (%) 2 (9.5)
Skin rash (%) 2 (9.5)
Leg cramps (%) 1 (4.8)
Total adverse effects (n) 21
Data are presented as mean ± standard deviation or number (percentage)
of subjects
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to failure to take OSCA (n = 22). As their compliance for
medication was less than 5%, we assessed serum IS levels in
these subjects at baseline and at 4 weeks after study enroll-
ment to mimic placebo treated controls. These subjects
showed no decrease in serum IS levels between baseline
and 4 weeks. Second, Hb levels were decreased among sub-
group of subjects after treatment of OSCA. Current Korean
National Health Insurance System (KNHIS) allow reim-
bursement for erythropoietin-stimulating agents (ESAs)
therapy in patients with eGFR < 30mL/min/1.73m2 and
Hb levels below 10.0 g/dL. Moreover, the target mainten-
ance Hb range is 10.0 to11.0 g/dL. Therefore, those subjects
with eGFR < 30mL/min/1.73m2 and Hb levels greater than
11.0 g/dL should have stopped their ESAs treatments until
Hb levels fell below 10.0 g/dL. In fact, subgroup analysis
demonstrated that only subjects with eGFR < 30mL/min/
1.73m2 and Hb levels greater than 11.0 g/dL showed sig-
nificant decrease in Hb levels during the study. Thus, we
speculated that decrease in Hb levels during the study
period was the result of reimbursement policy for ESA
treatment rather than by the OSCA treatment. Another
limitation of this study is the short study duration of 8
weeks. However, Tsubakihara et al. reported that 2 weeks
of oral adsorbent therapy can successfully reduce serum
levels of IS in advanced CKD patients [23]. Our study also
showed that after 4 weeks of OSCA administration, CKD
patients showed significant decrease in serum IS levels. Fi-
nally, nutritional or dietary compliance was not confirmed
by objective methods, such as assessment of 24-h urinary
excretion of urea. However, dietary education was provided
to all patients and follow-up dietary interviews showed no
significant changes in diet in any participant.
Conclusion
This study demonstrated that a new carbon adsorbent,
OSCA, reduced serum levels of IS in moderate to severe
CKD patients. In addition, no treatment-related severe
adverse effects were reported, and a high medication
compliance rate was noted. Future study is warranted to
evaluate whether OSCA has further beneficial effects in
terms of reduction in the development of renal events in
addition to reducing serum levels of uremic toxins.
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